Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.41 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6114563 | 0.85 | PTGS2 (0.50) | PTGS2KMT2AKIF11CA1CA2 | |
| SCHEMBL8394618 | 0.83 | ALDH1A1 (0.52) | KMT2ACA1CA2ALDH1A1BCHE | |
| SCHEMBL21595326 | 0.83 | PTGS2 (0.49) | PTGS2KMT2AKIF11CA1CA2 | |
| SCHEMBL3036379 | 0.83 | PTGS2 (0.50) | PTGS2KMT2AKIF11CA1CA2 | |
| SCHEMBL28638935 | 0.81 | HSD11B1 (0.35) | PTGS2KMT2ACA1CA2ALDH1A1 | |
| SCHEMBL15000821 | 0.81 | ALDH1A1 (0.54) | PTGS2KMT2AKIF11CA1CA2 | |
| SCHEMBL28366767 | 0.80 | PTGS2 (0.48) | PTGS2KMT2AKIF11CA1CA2 | |
| SCHEMBL11888416 | 0.79 | BCHE (0.48) | PTGS2KIF11BCHEACHEPTGS1 | |
| SCHEMBL3938489 | 0.79 | KIF11 (0.43) | PTGS2KMT2AKIF11CA1CA2 | |
| SCHEMBL2267244 | 0.79 | CA1 (0.45) | PTGS2KMT2ACA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024006773-A1 | METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2024006773-A1 | METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230416250-A1 | METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INCORPORATED | 2023-12-28 | — | — | US | disclosed |
| EP-4185296-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | Merck Sharp & Dohme LLC (US) | 2023-05-31 | — | — | EP | disclosed |
| US-8591757-B2 | Electrolyte composition and ionic liquid | KANEKA CORPORATION (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8389564-B2 | Proteasome inhibitors | TRIPHASE RESEARCH AND DEVELOPMENT I CORP. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20120270919-A1 | PROTEASOME INHIBITORS | NEREUS PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8227503-B2 | Proteasome inhibitors | NEREUS PHARMACEUTICALS, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110172285-A1 | PROTEASOME INHIBITORS | NEREUS PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-7910616-B2 | Proteasome inhibitors | NEREUS PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100213402-A1 | ELECTROLYTE COMPOSITION AND IONIC LIQUID | KANEKA CORPORATION (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20090298906-A1 | PROTEASOME INHIBITORS | NEREUS PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270919-A1 | PROTEASOME INHIBITORS | PSMB1, PSME1, PSME3 | PTGS2 2304/4885KMT2A 1924/4885KIF11 3427/4885 |
| US-20230416250-A1 | METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, NR5A1 | PTGS2 1099/4885KMT2A 2066/4885KIF11 2345/4885 |
| US-20090298906-A1 | PROTEASOME INHIBITORS | PSMB1, PSME1, PSME3 | PTGS2 2304/4885KMT2A 1924/4885KIF11 3427/4885 |
| US-20110172285-A1 | PROTEASOME INHIBITORS | PSMB1, PSME1, PSME3 | PTGS2 2304/4885KMT2A 1924/4885KIF11 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.